RETRACTED ARTICLE: Suppression of the xCT–CD44v antiporter system sensitizes triple-negative breast cancer cells to doxorubicin

Glutamine Sensitivity Analysis Identifies the xCT Antiporter as a Common Triple-Negative Breast Tumor Therapeutic Target

(2013) Luika A. Timmerman et al.   CANCER CELL

xCT Inhibition Depletes CD44v-Expressing Tumor Cells That Are Resistant to EGFR-Targeted Therapy in Head and Neck Squamous Cell Carcinoma

(2013) M. Yoshikawa et al.   CANCER RESEARCH

Live-cell single-molecule imaging reveals clathrin and caveolin-1 dependent docking of SMAD4 at the cell membrane

(2013) Yong Yang et al.   FEBS LETTERS

Functional interplay between the DNA-damage-response kinase ATM and ARF tumour suppressor protein in human cancer

(2013) Georgia Velimezi et al.   NATURE CELL BIOLOGY

Redox regulation in stem-like cancer cells by CD44 variant isoforms

(2013) O Nagano et al.   ONCOGENE

Polyarginine Induces an Antitumor Immune Response through Binding to Toll-Like Receptor 4

(2013) Yong Yang et al.   Small

Targeting triple-negative breast cancer: optimising therapeutic outcomes

(2012) K. Gelmon et al.   ANNALS OF ONCOLOGY

Targeted therapy for triple-negative breast cancer: Where are we?

(2012) Michael J. Duffy et al.   INTERNATIONAL JOURNAL OF CANCER

Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells

(2012) Oliver D. K. Maddocks et al.   NATURE

Doxorubicin acts via mitochondrial ROS to stimulate catabolism in C2C12 myotubes

(2011) Laura A. A. Gilliam et al.   AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY

CD44 Variant Regulates Redox Status in Cancer Cells by Stabilizing the xCT Subunit of System xc− and Thereby Promotes Tumor Growth

(2011) Takatsugu Ishimoto et al.   CANCER CELL

Cancer cell killing via ROS: To increase or decrease, that is the question

(2010) Jie Wang et al.   CANCER BIOLOGY & THERAPY

Triple-Negative Breast Cancer

(2010) Steven J. Isakoff   CANCER JOURNAL

Histological and molecular types of breast cancer: is there a unifying taxonomy?

(2009) Britta Weigelt et al.   Nature Reviews Clinical Oncology

Targeting cancer cells by ROS-mediated mechanisms: a radical therapeutic approach?

(2009) Dunyaporn Trachootham et al.   NATURE REVIEWS DRUG DISCOVERY

The xc− cystine/glutamate antiporter: a mediator of pancreatic cancer growth with a role in drug resistance

(2008) M Lo et al.   BRITISH JOURNAL OF CANCER

Locoregional Treatment Outcomes After Multimodality Management of Inflammatory Breast Cancer

(2008) Ian J. Bristol et al.   INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS